We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Legal & General Group Plc | LSE:LGEN | London | Ordinary Share | GB0005603997 | ORD 2 1/2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.50 | -0.61% | 243.50 | 243.40 | 243.60 | 244.20 | 241.80 | 243.50 | 3,207,615 | 10:53:57 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Ins Agents,brokers & Service | 36.48B | 457M | 0.0764 | 31.86 | 14.55B |
From Apr 2019 to Apr 2024
TIDMIMM TIDMLGEN
RNS Number : 2167X
Immupharma PLC
17 February 2017
17 FEBRUARY 2017
NOTIFICATION OF INTEREST BY LEGAL & GENERAL
ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of 3,774,714 million Ordinary Shares in the capital of the Company.
Full disclosure of the TR1 is shown below:
Hot Features
Premium
1. Identity of the issuer or ImmuPharma Plc
the underlying issuer
of existing shares to which
voting rights are
attached:
------------------------------------------------------------ -----------------------------
2. Reason for the notification (please tick the appropriate
box or boxes):
-------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights Yes
--------------------------------------------------------------- --------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached.
--------------------------------------------------------------- --------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
--------------------------------------------------------------- --------------------------
An event changing the breakdown of voting rights
--------------------------------------------------------------- --------------------------
Other (please
specify):
-------------------------------------------------------- ----- --------------------------
3. Full name of person(s) Legal & General Group Plc
subject to the (L&G)
notification obligation:
---------------------------------------------------------- -------------------------------
4. Full name of shareholder(s) Legal & General Assurance
(if different from 3.): Society Limited (LGAS)
---------------------------------------------------------- -------------------------------
15 February 2017
5. Date of the transaction
and date on
which the threshold is
crossed or
reached:
---------------------------------------------------------- -------------------------------
6. Date on which issuer 16 February 2017
notified:
---------------------------------------------------------- -------------------------------
7. Threshold(s) that is/are L&G (Below 3%)
crossed or
reached:
---------------------------------------------------------- -------------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------ ---------------------------------- --------------------------------------------------------------------
Number Number Number of % of voting
of of voting rights
Shares Voting rights
Rights
------------ ---------------- ---------------- ------------------------ -------------------------
Number Direct Indirect Direct Indirect
of shares
------------ ------------ ------------ --------------- ---------- ------------ ------------ -----------
ORD GBP 3,774,714 Below Below - Below -
0.10 3% 3% 3%
------------ ---------------------------------- --------------- ---------- ------------ ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Number of voting
Type of Expiration Exercise/ rights that % of voting
financial date Conversion may be rights
instrument Period acquired if
the
instrument
is
exercised/
converted.
---------------- -------------- --------------------------------- -------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights
instrument period refers to
-------------- -------------- -------------- ----------------- -------------------------- -----------------------
Nominal Delta
-------------- -------------- -------------- ----------------- -------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
-------------------------------------------------- ------------------------------------------------------------------
Below 3%
----------------------------------------------------------------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
--------------------------------------------------------------------------------------------------------------------
Legal & General Group Plc (Direct and
Indirect) (Group) ( Below 5% = Total
Position)
Legal & General Investment Management
(Holdings) Limited (LGIMH) (Direct and
Indirect) ( Below
5% = Total Position)
Legal & General Investment Management
Limited (Indirect) (LGIM) ( Below 5% =
Total Position)
Legal & General Group Plc (Direct) (L&G) ( Below 3% = LGAS, LGPL & PMC)
Legal & General Investment Management Legal & General Insurance Holdings Limited
(Holdings) Limited (Direct) (LGIMHD) (Direct) (LGIH)
Legal & General Assurance (Pensions Legal & General Assurance Society Limited
Management) Limited (PMC) (LGAS & LGPL)
Legal & General Pensions Limited (Direct)
(LGPL)
Proxy Voting:
--------------------------------------------------------------------------------------------------------------------
10. Name of the proxy holder: N/A
----------------------------------------------------------------------------- -------------------------------------
11. Number of voting rights proxy N/A
holder will cease to hold:
----------------------------------------------------------------------------- -------------------------------------
12. Date on which proxy holder will N/A
cease to hold
voting rights:
----------------------------------------------------------------------------- -------------------------------------
Notification using the total
13. Additional information: voting rights figure of 124,638,362
----------------------------------------------------------------------------- -------------------------------------
14. Contact name: Victoria Davies (LGIM)
----------------------------------------------------------------------------- -------------------------------------
15. Contact telephone number: 029 2035 4147
----------------------------------------------------------------------------- -------------------------------------
-Ends-
For further information please
contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.org) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413496
Northland Capital Partners Limited
(NOMAD & Broker)
Patrick Claridge, David Hignell,
Michael Mackintosh, Corporate
Finance +44 (0)20 3861
Rob Rees, Corporate Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLZDLFFDLFBBBF
(END) Dow Jones Newswires
February 17, 2017 09:04 ET (14:04 GMT)
1 Year Legal & General Chart |
1 Month Legal & General Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
